MHRA grants conditional marketing authorization for AbbVie’s Tepkinly to treat aggressive blood cancer
AbbVie today announced that the UK Medicines and Healthcare products Regulatory Agency has granted conditional Marketing Authorisation for Tepkinly® (epcoritamab) as a monotherapy for the treatment of adults with relapsed…